CR10736A - Composiciones y metodos relacionados con los anticuerpos del receptor del glucagon - Google Patents

Composiciones y metodos relacionados con los anticuerpos del receptor del glucagon

Info

Publication number
CR10736A
CR10736A CR10736A CR10736A CR10736A CR 10736 A CR10736 A CR 10736A CR 10736 A CR10736 A CR 10736A CR 10736 A CR10736 A CR 10736A CR 10736 A CR10736 A CR 10736A
Authority
CR
Costa Rica
Prior art keywords
antibodies
compositions
methods related
methods
treatment
Prior art date
Application number
CR10736A
Other languages
English (en)
Inventor
Hai Yan
Shaw-Fen Sylvia Hu
Thomas C Boone
Richard A Lindberg
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR10736A publication Critical patent/CR10736A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)

Abstract

La presente divulgacion suministra composiciones y metodos relacionados con proteinas de union a antigenos, en particular, anticuerpos que se unen especificamente al receptor de glucagon de origen humano. La divulgacion provee acido nucleicos que codifican para dichas proteinas de union a antigenos y anticuerpos y metodos para preparar y utilizar dicho anticuerpo para el tratamiento y la prevencion de la diabetes de tipo 2 y trastornos relacionados mediante la administracion de dichos anticuerpos a un individuo que requiere dicho tratamiento.
CR10736A 2006-09-20 2009-04-17 Composiciones y metodos relacionados con los anticuerpos del receptor del glucagon CR10736A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84620206P 2006-09-20 2006-09-20
US96897707P 2007-08-30 2007-08-30

Publications (1)

Publication Number Publication Date
CR10736A true CR10736A (es) 2009-06-30

Family

ID=39201088

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10736A CR10736A (es) 2006-09-20 2009-04-17 Composiciones y metodos relacionados con los anticuerpos del receptor del glucagon

Country Status (19)

Country Link
US (2) US7947809B2 (es)
EP (1) EP2074149B1 (es)
JP (1) JP5513888B2 (es)
KR (1) KR20090059161A (es)
CN (1) CN101589062B (es)
AR (1) AR062895A1 (es)
AU (1) AU2007297652B2 (es)
BR (1) BRPI0715017A8 (es)
CA (1) CA2662613C (es)
CL (1) CL2007002668A1 (es)
CR (1) CR10736A (es)
EA (1) EA200970262A1 (es)
ES (1) ES2444012T3 (es)
IL (1) IL197241A0 (es)
MX (2) MX2009003093A (es)
NO (1) NO20091534L (es)
PE (1) PE20080846A1 (es)
TW (1) TW200820985A (es)
WO (1) WO2008036341A2 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2009000586A1 (es) * 2008-03-27 2010-06-04 Lilly Co Eli Fragmento fab o anticuerpo monoclonal humanizado que lo comprende que se une a receptor de glucagon humano/glucr, de rata, de raton, y mono cinomolgus; vector que comprende polinuccleotido codificante; celula huesped que lo comprende; composicion farmaceutica; uso para tratar diabetes tipo 1 o 2, o para la perdida de peso
JP2013503626A (ja) * 2009-09-08 2013-02-04 ネオファーム シーオー．， エルティーディー． グルカゴン受容体に対する抗体と、それらの使用
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
WO2013059531A1 (en) * 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
JP6050671B2 (ja) * 2012-12-07 2016-12-21 ダイキン工業株式会社 空気調和装置の配管ユニットの製造方法および空気調和装置の施工方法
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
WO2014181229A2 (en) * 2013-05-07 2014-11-13 Rinat Neuroscience Corp. Anti-glucagon receptor antibodies and methods of use thereof
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
EP3662928A1 (en) * 2014-04-10 2020-06-10 OBI Pharma Inc. Antibodies binding to tumour associated carbohydrate antigens, pharmaceutical compositions and uses thereof
US10156562B2 (en) 2014-05-16 2018-12-18 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
MX388503B (es) 2014-06-08 2025-03-11 Remd Biotherapeutics Inc Uso de anticuerpos antagonistas del receptor de glucagon en el tratamiento de diabétes tipo 1.
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
KR102594117B1 (ko) 2014-10-01 2023-10-26 메디뮨 리미티드 티카그렐로에 대한 항체 및 이의 사용 방법
CN111018987B (zh) * 2014-12-05 2023-11-21 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其应用
US10610504B2 (en) * 2014-12-23 2020-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Alpha-cell re-generation combined with conversion to beta cells
AU2016206457B2 (en) 2015-01-16 2021-11-11 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ROR1
KR20170138456A (ko) * 2015-04-02 2017-12-15 렘드 바이로테라퓨틱스, 인크 글루카곤 수용체 길항 항체를 이용한 비만 및 비알콜성 지방간 질환 또는 비알콜성 지방간염의 치료 방법
CA2999747A1 (en) * 2015-09-04 2017-03-09 Remd Biotherapeutics, Inc. Methods for treating heart failure using glucagon receptor antagonistic antibodies
US20190062441A1 (en) * 2015-10-07 2019-02-28 Remd Biotherapeutics, Inc. Methods For Treating Rare Genetic Disorders Using Glucagon Receptor Antagonistic Antibodies
KR101896882B1 (ko) 2015-11-30 2018-09-11 앱클론(주) Vegfr2에 특이적으로 결합하는 항체
WO2017120261A1 (en) * 2016-01-04 2017-07-13 Remd Biotherapeutics, Inc. Methods of treating type 2 diabetes mellitus using glucagon receptor antagonistic antibodies
JP7187035B2 (ja) * 2016-08-03 2022-12-12 アールイーエムディー バイオセラピューティクス，インコーポレイテッド 癌を治療するためのグルカゴン受容体アンタゴニストとｐｉ３ｋ経路阻害剤との組み合わせ
KR102708864B1 (ko) 2016-08-30 2024-09-25 리제너론 파마슈티칼스 인코포레이티드 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법
US20190248888A1 (en) 2016-10-20 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
PE20191404A1 (es) 2017-01-27 2019-10-04 Ngm Biopharmaceuticals Inc Proteinas de union al receptor de glucagon y metodos para usarlas
JP2020510646A (ja) * 2017-02-20 2020-04-09 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質
JP7672196B2 (ja) 2017-03-14 2025-05-07 アムジエン・インコーポレーテツド 細胞培養において産生される抗体の総非フコシル化グリコフォームの調節
CN107011414B (zh) * 2017-05-31 2020-04-24 浙江省农业科学院 具有降血糖功能的三肽spf及其用途
JP7781519B2 (ja) 2017-08-22 2025-12-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法
KR20200135781A (ko) 2018-03-26 2020-12-03 암젠 인크 세포 배양에서 생산된 항체의 총 비푸코실화 당형태
CN110357959B (zh) * 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
US10961315B2 (en) 2018-07-27 2021-03-30 Ngm Biopharmaceuticals, Inc. Method of treating type I diabetes by administering a combination of a glucagon receptor antagonist and an anti-CD3 antibody
BR112021011595A2 (pt) 2018-12-21 2021-11-30 Jiangsu Hengrui Medicine Co Proteína biespecífica
JP7313730B2 (ja) * 2019-05-29 2023-07-25 ヘッジホッグ，インコーポレイテッド エンドセリン受容体ａ結合力が向上した抗体
AU2020329217A1 (en) * 2019-08-12 2022-07-28 Aptevo Research And Development Llc 4-1BB and OX40 binding proteins and related compositions and methods, antibodies against 4-1BB, antibodies against OX40
MX2022003461A (es) 2019-09-26 2022-04-19 Amgen Inc Metodos de produccion de composiciones de anticuerpos.
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
CA3190667A1 (en) * 2020-08-26 2022-03-03 Aaron Sato Methods and compositions relating to glp1r variants
MX2023004364A (es) 2020-10-15 2023-05-03 Amgen Inc Glucanos no emparejados relativos en metodos de produccion de anticuerpos.
AU2021411581A1 (en) * 2020-12-31 2023-07-06 Novarock Biotherapeutics, Ltd. Antibodies to tnfr2 and uses thereof
WO2022182664A1 (en) * 2021-02-23 2022-09-01 10X Genomics, Inc. A method for epitope binning of novel monoclonal antibodies
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
AU2022361382A1 (en) 2021-10-05 2024-03-28 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776725A (en) * 1992-08-28 1998-07-07 Zymogenetics, Inc. Recombinant production of glucagon receptors
US5639863A (en) * 1994-06-21 1997-06-17 Dan; Michael D. Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
US5889167A (en) * 1996-05-22 1999-03-30 Merck & Co., Inc. Synthetic glucagon binding proteins
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US6909031B2 (en) 2000-12-06 2005-06-21 Deltagen, Inc. Transgenic mice containing glucagon receptor gene disruptions
US6864069B2 (en) 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
WO2006005469A2 (en) * 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
WO2006068953A2 (en) * 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
WO2006081139A2 (en) * 2005-01-26 2006-08-03 Abgenix, Inc. Antibodies against interleukin-1 beta

Also Published As

Publication number Publication date
WO2008036341A2 (en) 2008-03-27
CN101589062B (zh) 2014-08-20
NO20091534L (no) 2009-04-28
AU2007297652B2 (en) 2012-02-16
EA200970262A1 (ru) 2009-10-30
CA2662613A1 (en) 2008-03-27
CL2007002668A1 (es) 2008-05-09
KR20090059161A (ko) 2009-06-10
US8158759B2 (en) 2012-04-17
US20110223160A1 (en) 2011-09-15
WO2008036341A3 (en) 2009-02-05
CN101589062A (zh) 2009-11-25
BRPI0715017A8 (pt) 2018-04-03
MX2009003093A (es) 2009-06-05
TW200820985A (en) 2008-05-16
AR062895A1 (es) 2008-12-10
MX353319B (es) 2018-01-05
IL197241A0 (en) 2011-08-01
EP2074149B1 (en) 2013-11-06
AU2007297652A1 (en) 2008-03-27
US7947809B2 (en) 2011-05-24
BRPI0715017A2 (pt) 2013-05-28
PE20080846A1 (es) 2008-08-23
EP2074149A2 (en) 2009-07-01
JP2010504331A (ja) 2010-02-12
JP5513888B2 (ja) 2014-06-04
US20090041784A1 (en) 2009-02-12
CA2662613C (en) 2014-01-28
ES2444012T3 (es) 2014-02-21

Similar Documents

Publication Publication Date Title
CR10736A (es) Composiciones y metodos relacionados con los anticuerpos del receptor del glucagon
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
MX357193B (es) Moleculas de union anti-alfa sinucleina.
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
AR083747A1 (es) Anticuerpos anti-il-23
CO7250445A2 (es) Proteínas de unión a antígeno st2
MX2011011754A (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b.
NZ706377A (en) Il-6 antagonists and uses thereof
MX2020013062A (es) Anticuerpos anti proteina relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticoides (gitr) y sus metodos de uso.
SG178886A1 (en) Humanized anti-cdcp1 antibodies
TN2015000247A1 (en) Bcma antigen binding proteins
SA112330988B1 (ar) أجسام مضادة تخص trop-2 واستخداماتها
IN2014CN03936A (es)
CY1115639T1 (el) Διειδικα αγωνιστικα αντισωματα υποδοχεα θανατου
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
UY32341A (es) Proteínas de unión antígeno novedosas
BRPI0821777B8 (pt) anticorpo biespecífico bivalente, método para a preparação do mesmo e composição
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
NZ593964A (en) Human anti-alpha-synuclein autoantibodies
UY31533A1 (es) Moleculas de enlace al receptor humano ox40
AR073140A1 (es) Anticuerpos anti-il-23r disenados
AR077972A1 (es) Anticuerpos contra cdcp1 destinados al tratamiento del cancer
CY1118046T1 (el) Πρωτεϊνες δεσμευσης με αντιγονο ειδικες για το συστατικο ρ αμυλοειδους ορου
PE20191404A1 (es) Proteinas de union al receptor de glucagon y metodos para usarlas
NZ631118A (en) Methods for treating nasal polyposis by administering an il-4r antagonist

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)